88 research outputs found
Head-to-head intra-individual comparison of [Ga-68]-FAPI and [F-18]-FDG PET/CT in patients with bladder cancer
DATA AVAILABILITY : The data used and/or analyzed during the current study are available from the corresponding author on reasonable request.Please read abstract in the article.Open Access funding enabled and organized by Projekt DEAL.https://link.springer.com/journal/11307hj2023Nuclear Medicin
Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines
Histone deacetylase 8 is deregulated in urothelial cancer but not a target for efficient treatment
Complications and health-related quality of life after robot-assisted versus open radical cystectomy: a systematic review and meta-analysis of four RCTs
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial
Few treatments with a distinct mechanism of action are available for patients with platinum-refractory advanced or metastatic urothelial carcinoma. We assessed the efficacy and safety of treatment with docetaxel plus either ramucirumab-a human IgG1 VEGFR-2 antagonist-or placebo in this patient population
491 HDAC (HISTONE DEACETYLASE) EXPRESSION PATTERNS IN UROTHELIAL CANCER AND THEIR IMPACT ON THE ACTION OF HDAC INHIBITORS
Prognostic factors in second-line treatment of urothelial cancers with gemcitabine and paclitaxel: German Association of Urological Oncology (AUO) trial AB 20/99.
Elicitation of health state utilities associated with progression from Bacillus Calmette-Guerin (BCG) unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)
Objectives: The treatments for high-grade non-muscle invasive bladder cancer (NMIBC) vary between bladder preserving intravesical approaches and radical cystectomy. The impact of these treatments on health-related quality of life may vary widely. The purpose of this study was to elicit the general public’s perspective on quality of life, measured as utility scores associated with treatment for Bacillus Calmette-Guerin (BCG)-unresponsive NMIBC and disease progression, for supporting economic evaluation of newly developed treatments for NMIBC. Materials and Methods: Part I involved the development and testing of health states describing NMIBC, which was informed by a rapid review, expert input and a patient advisor. Part II involved elicitation of societal utility values for the different health states. Time trade-off (TTO) interviews were conducted with members of the UK general public. Five health states described different NMIBC scenarios including disease recurrence and progression. Participants ranked each health state, followed by the TTO valuation exercise. Descriptors included NMIBC symptom severity, impact and treatment characteristics. Results: In total, 202 members of the general public participated. The mean age was 46 (standard deviation [SD] 14.6) years. Sample mean (SD) EQ-5D-5L visual analogue scale (VAS) and index scores were 83.2 (12.3) and 0.89 (0.18), respectively. Mean utilities were 0.781 for No High-Grade Recurrence, 0.586 for High-Grade Recurrence, 0.572 for > 1-Year Post-cystectomy and 0.283 for metastatic disease. The First Year Post-cystectomy path health state had a mean utility of 0.288. Pairwise comparisons found statistically significant differences between utilities (p 1-Year Post-cystectomy (p = 0.524). There were significant differences in utility scores by age and employment status. Conclusion: This study provides utility scores for health states describing living with NMIBC, which is associated with a significant health-related quality-of-life burden. These values address an existing gap in available data and have the potential to be used in models evaluating the cost-effectiveness of both current and newly developed treatments for bladder cancer
- …